
Ozempic Wars | The Hundred-Year Duel | 1
Business Wars
00:00
Should Novo Nordisk pursue weight loss market?
David Brown outlines the internal risk debate over positioning Ozempic for weight loss amid past diet-drug controversies.
Play episode from 15:31
Transcript


